找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: New Drug Development; An Introduction to C J. Rick Turner Book 2010Latest edition Springer Science+Business Media, LLC 2010 Clinical.Develo

[復(fù)制鏈接]
查看: 48155|回復(fù): 59
樓主
發(fā)表于 2025-3-21 17:15:59 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱New Drug Development
副標(biāo)題An Introduction to C
編輯J. Rick Turner
視頻videohttp://file.papertrans.cn/666/665160/665160.mp4
概述Discuss the latest developments in the realm of drug safety, and expands its coverage of clinical trials considerably Provides a conceptual introduction to statistics and illustrates its important rol
圖書封面Titlebook: New Drug Development; An Introduction to C J. Rick Turner Book 2010Latest edition Springer Science+Business Media, LLC 2010 Clinical.Develo
描述New Drug Development: Second Edition provides an overview of the design concepts and statistical practices involved in therapeutic drug development. This wide spectrum of activities begins with identifying a potentially useful drug candidate that can perhaps be used in the treatment or prevention of a condition of clinical concern, and ends with marketing approval being granted by one or more regulatory agencies. In between, it includes drug molecule optimization, nonclinical and clinical evaluations of the drug’s safety and efficacy profiles, and manufacturing considerations. The more inclusive term lifecycle drug development can be used to encompass the postmarketing surveillance that is conducted all the time that a drug is on the market and being prescribed to patients with the relevant clinical condition. Information gathered during this time can be used to modify the drug (for example, dose prescribed, formulation, and mode of administration) in terms of its safety and its effectiveness. The central focus of the first edition of this book is captured by its subtitle, ‘Design, Methodology, and Analysis‘. Optimum quality study design and experimental research methodology must b
出版日期Book 2010Latest edition
關(guān)鍵詞Clinical; Development; Drug; Introduction; Trial; Turner; methodology
版次2
doihttps://doi.org/10.1007/978-1-4419-6418-2
isbn_softcover978-1-4939-0091-6
isbn_ebook978-1-4419-6418-2
copyrightSpringer Science+Business Media, LLC 2010
The information of publication is updating

書目名稱New Drug Development影響因子(影響力)




書目名稱New Drug Development影響因子(影響力)學(xué)科排名




書目名稱New Drug Development網(wǎng)絡(luò)公開度




書目名稱New Drug Development網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱New Drug Development被引頻次




書目名稱New Drug Development被引頻次學(xué)科排名




書目名稱New Drug Development年度引用




書目名稱New Drug Development年度引用學(xué)科排名




書目名稱New Drug Development讀者反饋




書目名稱New Drug Development讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 20:22:50 | 只看該作者
板凳
發(fā)表于 2025-3-22 01:57:09 | 只看該作者
New Drug Development,novel chemical compound, i.e., a new chemical entity (NCE) or new molecular entity (NME), as its active ingredient. In the case of biologicals, attention focuses on proteins that are produced via the large-scale cultivation of microbial or mammalian cells.
地板
發(fā)表于 2025-3-22 06:21:09 | 只看該作者
5#
發(fā)表于 2025-3-22 08:52:53 | 只看該作者
Sample Size Estimation, an understanding of important concepts, including statistical significance and clinical significance, before reading about sample size estimation. Addressing sample size estimation at this point also allows a whole (short) chapter to be dedicated to this topic, thereby acknowledging its importance in clinical research.
6#
發(fā)表于 2025-3-22 14:46:51 | 只看該作者
Cardiac and Cardiovascular Safety Assessments,ng). In this chapter discussions focus on analogous evaluations in humans if a sponsor decides to move the drug molecule into clinical trials. At this point, the term investigational drug can be adopted.
7#
發(fā)表于 2025-3-22 19:43:04 | 只看該作者
8#
發(fā)表于 2025-3-22 23:20:37 | 只看該作者
9#
發(fā)表于 2025-3-23 05:19:21 | 只看該作者
General Safety Assessments,cussions of safety now move to safety assessments in clinical trials. This chapter discusses general safety assessments, and Chapter 14 addresses specialized cardiac and cardiovascular safety assessments that have recently become critical components of new drug development. Postmarketing surveillance is discussed later in Chapter 16.
10#
發(fā)表于 2025-3-23 07:34:32 | 只看該作者
Manufacturing Small Molecule Drugs and Biologicals,l. Successfully producing the drug candidate for nonclinical testing and clinical trials and manufacturing the drug for postapproval marketing are critical. Moreover, their complexity and difficulty should not be underestimated.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-11 13:50
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
柳州市| 高邑县| 县级市| 万盛区| 启东市| 二连浩特市| 武邑县| 沽源县| 巢湖市| 伊吾县| 定陶县| 瑞金市| 永安市| 商南县| 阆中市| 布拖县| 义马市| 剑阁县| 蓬莱市| 唐山市| 肥城市| 桓仁| 牡丹江市| 竹北市| 侯马市| 平阴县| 宿州市| 乌什县| 斗六市| 米易县| 江川县| 白玉县| 长丰县| 阳高县| 连云港市| 琼结县| 阿克陶县| 新疆| 莆田市| 都昌县| 那坡县|